OTLK

Outlook Therapeutics, Inc.

7.91 USD
+0.28 (+3.67%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Outlook Therapeutics, Inc. stock is up 0.13% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 8 June’s closed higher than May.

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.